Meeting
2021 ASCO Annual Meeting
The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.
Authors
Giuseppe Lombardi
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Giuseppe Lombardi , Silvia Giunco , Francesco Cavallin , Chiara Angelini , Mario Caccese , Giulia Cerretti , Pasquale De Bonis , Anita De Rossi , Vittorina Zagonel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2053)
DOI
10.1200/JCO.2021.39.15_suppl.2053
Abstract #
2053
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
First Author: Masamichi Takahashi
Poster
2021 ASCO Annual Meeting
Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.
First Author: Yasmeen Rauf
Poster
2020 ASCO Virtual Scientific Program
Socioeconomic disparities in MGMT promoter methylation testing for glioblastoma patients.
First Author: Bryan Iorgulescu